Skip to content

Study on Safety and Effectiveness of Regional Citrate Anticoagulation in Children Undergoing Continuous Kidney Support in Critically Ill Children.

Safety and Efficacy of Regional Citrate Anticoagulation in Pediatric CRRT - NIL

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2025/09/094862
Enrollment
10
Registered
2025-09-16
Start date
Unknown
Completion date
Unknown
Last updated
2025-12-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K720- Acute and subacute hepatic failure Health Condition 2: E877- Fluid overload Health Condition 3: E889- Metabolic disorder, unspecified Health Condition 4: N178- Other acute kidney failure Health Condition 5: E878- Other disorders of electrolyte andfluid balance, not elsewhere classified Health Condition 6: E883- Tumor lysis syndrome

Interventions

Intervention1: Continuous renal replacement therapy: In a critically ill child Intervention2: Nil: Nil Intervention3: Nil: Nil Intervention4: Nil: Nil

Sponsors

Dr Yashkumar Prajapati
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Pediatric patient who require continuous renal replacement therapy (CRRT) with regional citrate anticoagulation (RCA).

Exclusion criteria

Exclusion criteria: (1) Patients are already on systemic anticoagulation, such as heparin or warfarin. (2) Known inherited or acquired disorders of calcium or citrate metabolism, e.g. primary hypoparathyroidism, mitochondrial citrate transport defects.

Design outcomes

Primary

MeasureTime frame
To determine proportion of patients showing survival of CRRT circuit.Timepoint: At 48 hours

Secondary

MeasureTime frame
To determine survival of CRRT circuit without citrate accumulation.Timepoint: At 72 hours;To measure incidence of severe bleeding, electrolyte imbalance, metabolic acidosis.Timepoint: Within 72 hours

Countries

India

Contacts

Public ContactDr Arvind Bagga

INDRAPRASTHA APOLLO HOSPITAL

arvindbagga@hotmail.com9810590809

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026